

Efficient Catalytic Enantioselective Nazarov Cyclizations of Divinyl Ketoesters

Zhou Xu^{a,b}, Hai Ren^a, Lijia Wang^{a*}, Yong Tang^{a*}

^a State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China.

^b Xuzhou Medical College, 209 Tongshan Road, Xuzhou 221004, China

E-mail: wanglijia@sioc.ac.cn; tangy@sioc.ac.cn; Fax:+86-21-54925078

Supporting Information

Contents


1. General information	S2
2. Screening the amount of water.....	S3
3. Typical Procedure for the asymmetric Nazarov cyclization	S4
4. Chemical transformation of 2a to 3a	S12
5. Crystal data of 1a	S13
6. Reference.....	S14
7. ¹ H NMR and ¹³ C NMR Spectra of Compounds	S15
8. HPLC spectra of the products	S27

1. General information

Unless stated otherwise, all reactions were carried out under an atmosphere of Ar using standard Schlenk techniques. All solvents and reagents were obtained from commercial sources and were purified according to standard procedures before use. ^1H NMR spectra were recorded on a VarianMercury 300 MHz or Varian Mercury 400 MHz or Agilent Mercury 400 MHz spectrometer in chloroform-d. All signals were reported in ppm with the internal TMS signal at 0.0 ppm or chloroform signal at 7.26 ppm as a standard. Data for ^1H NMR were recorded as follows: chemical shift (δ , ppm), multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet or unresolved, coupling constant(s) in Hz, integration). ^{13}C NMR spectra were recorded on a Varian Mercury 75 MHz or Agilent Mercury 100 MHz spectrometer in chloroform-d. All signals are reported in ppm with the internal chloroform signal at 77.0 ppm as a standard. Enantiomeric ratios were obtainedusing a PerkinElmer series 200 equipped with an UV-VIS detector using one of the following chiral HPLC columns: Chiralcel AD-3 and Chiralcel AD-H column. Infrared spectra were recorded on a Perkin-Elmer Spectrum One FT-IR spectrometer. Chromatography: Flash chromatography was performed on silica gel (Merck Silica Gel 60, 300-400 mesh). TLC was performed on aluminium backed silica plates (60F254, 0.2 mm) which were developed using standard visualising agents. High resolution mass spectra were recorded on a Micromass Analytical Autospec spectrometer.

The substrates **1a-1n** were synthesized according to the literature with similar methods.¹⁻²

2. Screening the amount of water




Entry	H ₂ O (uL)	time (h)	con. (%) ^b	ee (%) ^c
1	0	11	>99	85
2	2.3	11	99	90
3	5	15	93	90.5
4	10	15	47	90
5	15	15	16	89

^a All reactions were carried out with 10 mol% Cu(ClO₄)₂ and ligand **L7** under Ar atmosphere; ^b Determined by ¹H NMR; ^c Determined by chiral HPLC;

3. Typical Procedure for the Asymmetric Nazarov Cyclization


A solution of Cu(ClO₄)₂·6H₂O (7.4 mg, 0.02 mmol) and Ligand (9.2 mg, 0.02 mmol) in anhyd DCE (4.0 mL) was stirred at r.t. for 3 h, then 2-benzyliden-3-oxo-4,5-diphenylpent-4-enoic acid ethyl ester (**1a**, 76.5 mg, 0.20 mmol) was added, then stirred at 40 °C for 20 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography to afford **2a** (70.4 mg), as a white solid, EtOAc/petroleum ether 1/20, 92% yield with 90 % ee (Chiralcel AD-3, ⁱPrOH/hexanes = 10/90, 1.0 mL/min⁻¹, λ = 295 nm: t_R (major) = 7.9 min, t_R (minor) = 10.9 min); $[\alpha]_D^{20} = + 276.7^\circ$ ($c = 1.050$, CHCl₃); The absolute configuration of the major enantiomer is (1*R*, 5*S*) by the comparison of its rotation with the data reported.^[1-2] The product **2a** was unstable in the air and it is better to store under low temperature in Ar atmosphere.

(1*R*, 5*S*)-ethyl 2-oxo-3,4,5-triphenylcyclopent-3-enecarboxylate **2a**




92% yield with 90 % ee (Chiralcel AD-3, ⁱPrOH/hexanes = 10/90, 1.0 mL/min⁻¹, λ = 295 nm: t_R (major) = 7.9 min, t_R (minor) = 10.9 min); $[\alpha]_D^{25} = + 276.7^\circ$ ($c = 1.0500$, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 7.31-7.11 (m, 15H), 5.02 (d, J = 2.0 Hz, 1H), 4.29-4.24 (m, 2H), 3.64 (d, J = 2.4 Hz, 1H), 1.32 (t, J = 7.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 199.2, 169.8, 168.1, 140.2, 138.4, 133.7, 131.0, 129.5, 129.4, 128.8, 128.7, 128.1, 128.0, 127.4, 127.0, 62.3, 61.6, 50.7, 13.9; IR (Film) ν : 1704, 1634, 1144 cm⁻¹; HRMS (ESI) calcd for C₂₆H₂₃O₃⁺: 383.1642. Found: 383.1654.

(1*R*, 2*S*)-ethyl 2-(4-bromophenyl)-5-oxo-3,4-diphenylcyclopent-3-enecarboxylate **2b**



81% yield with 88% *ee* (Chiralcel AD-3, *i*PrOH/hexanes = 20/80, 1.0 mL/min⁻¹, λ = 300 nm; t_R (major) = 7.3 min, t_R (minor) = 8.6 min); $[\alpha]_D^{25} = + 112.7^\circ$ ($c = 1.4870$, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 7.37-7.31 (m, 5H), 7.27-7.20 (m, 3H), 7.17-7.15 (m, 4H), 7.03 (d, $J = 8.4$ Hz, 2H), 5.00 (d, $J = 2.8$ Hz, 1H), 4.31-4.25 (m, 2H), 3.57 (d, $J = 3.2$ Hz, 1H), 1.32 (t, $J = 7.2$ Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 198.9, 169.2, 168.0, 139.5, 138.9, 133.7, 132.1, 130.9, 129.8, 129.7, 129.4, 128.8, 128.4, 128.3(4), 128.3(2), 121.2, 62.2, 62.0, 50.2, 14.2; IR (Film) ν : 1705, 1488, 1177 cm⁻¹; HRMS (ESI) calcd for C₂₆H₂₂BrO₃⁺: 461.0747. Found: 461.0744.


**(1*R*, 2*S*)-ethyl 2-(3-bromophenyl)-5-oxo-3,4-diphenylcyclopent-3-enecarboxylate
2c**



80% yield with 85 % *ee* (Chiralcel AD-3, *i*PrOH/hexanes= 20/80, 1.0 mL/min⁻¹, λ = 300 nm; t_R (major) = 9.3 min, t_R (minor) = 13.6 min); $[\alpha]_D^{25} = + 288.2^\circ$ ($c = 0.9700$, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 7.31-7.06 (m, 12H), 6.72 (d, $J = 7.6$ Hz, 1H), 6.62 (d, $J = 7.2$ Hz, 2H), 4.95 (d, $J = 2.4$ Hz, 1H), 4.29-4.24 (m, 2H), 3.63 (d, $J = 2.8$ Hz, 1H), 1.30 (t, $J = 7.0$ Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 200.4, 170.8, 168.5, 156.6, 141.6, 138.5, 133.5, 130.8, 129.9, 129.6, 129.4, 128.7, 128.2, 128.1, 128.0,


119.1, 114.4, 114.3, 62.2, 62.0, 50.7, 13.8; IR (Film) ν : 1729, 1690, 1614, 1143 cm⁻¹; HRMS (ESI) calcd for C₂₆H₂₂BrO₃⁺: 461.0747. Found: 461.0748.

**(1*R*, 2*S*)-ethyl 2-(2-bromophenyl)-5-oxo-3,4-diphenylcyclopent-3-enecarboxylate
2d**



78% yield with 86% ee (Chiralcel AD-3, *i*PrOH/hexanes = 10/90, 1.0 mL/min⁻¹, λ = 297 nm; t_R (major) = 9.7 min, t_R (minor) = 15.7 min); $[\alpha]_D^{25} = + 280.3^\circ$ ($c = 0.7450$, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 7.54 (d, $J = 7.2$ Hz, 1H), 7.33-7.09 (m, 11H), 7.04-6.93 (m, 2H), 5.62 (s, 1H), 4.33-4.26 (m, 2H), 3.47 (s, 1H), 1.33 (t, $J = 7.2$ Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 199.4, 169.5, 168.1, 140.3, 139.5, 133.5, 133.0, 131.2, 130.0, 129.6, 128.9, 128.7, 128.4, 128.3, 128.2, 128.1, 124.8, 61.9, 61.7, 49.6, 14.2; IR (Film) ν : 1731, 1693, 1368, 1143, 1017 cm⁻¹; HRMS (ESI) calcd for C₂₆H₂₂BrO₃⁺: 461.0747. Found: 461.0748.


**(1*R*, 2*S*)-ethyl 2-([1,1'-biphenyl]-4-yl)-5-oxo-3,4-diphenylcyclopent-3-enecarboxylate
2e**



92% yield with 83% ee (Chiralcel AD-3, *i*PrOH/hexanes = 10/90, 1.0 mL/min⁻¹, λ =


300 nm: t_R (major) = 12.8 min, t_R (minor) = 17.5 min); $[\alpha]_D^{25} = + 250.5^\circ$ ($c = 1.1400$, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 7.52-7.15 (m, 19H), 5.07 (d, $J = 2.7$ Hz, 1H), 4.33-4.24 (m, 2H), 3.67 (d, $J = 2.7$ Hz, 1H), 1.33 (t, $J = 7.1$ Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) : δ 199.3, 169.8, 168.3, 140.2, 140.0, 139.5, 138.7, 134.0, 131.2, 129.7, 129.6, 128.9, 128.7, 128.3, 128.2, 128.1(9), 128.1, 127.6, 127.3, 126.8, 62.4, 61.9, 50.5, 14.1; IR (Film) ν : 1725, 1698, 1340, 1250, 1138 cm⁻¹; HRMS (ESI) calcd for C₃₂H₂₇O₃⁺: 459.1955. Found: 459.1956.

(1*R*, 5*S*)-ethyl 2-oxo-3,4-diphenyl-5-(4-(trifluoromethyl)phenyl)cyclopent-3-enecarboxylate 2f



83% yield with 84 % ee (SFC, ⁱPrOH/hexanes = 10/90, 1.0 mL/min⁻¹, $\lambda = 214$ nm: t_R (major) = 6.6 min, t_R (minor) = 8.8 min); $[\alpha]_D^{25} = + 258.8^\circ$ ($c = 0.6500$, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 7.49 (d, $J = 8.1$ Hz, 2H), 7.32-7.18 (m, 12H), 5.12 (d, $J = 3.0$ Hz, 1H), 4.31-4.26 (m, 2H), 3.58 (d, $J = 3.0$ Hz, 1H), 1.32 (t, $J = 7.2$ Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 198.6, 168.8, 167.9, 144.6 (d, $J = 1.1$ Hz), 139.1, 133.6, 130.9, 129.9, 129.7, 128.8, 128.4, 128.1, 126.0 (q, $J = 3.6$ Hz), 62.1, 50.4, 14.2; ¹⁹F NMR (282 MHz, CDCl₃) : δ -63.0; IR (Film) ν : 1731, 1703, 1322, 1110 cm⁻¹; HRMS (ESI) calcd for C₂₇H₂₂F₃O₃⁺: 451.1516. Found: 451.1518.


(1*R*,2*S*)-ethyl 2-(naphthalen-1-yl)-5-oxo-3,4-diphenylcyclopent-3-enecarboxylate 2g



2g

89% yield with 86% *ee* (Chiralcel AD-H, *i*PrOH/hexanes = 10/90, 0.7 mL/min⁻¹, λ = 296 nm; t_R (major) = 9.5 min, t_R (minor) = 11.3 min); $[\alpha]_D^{25} = + 296.5^\circ$ ($c = 0.5000$, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 8.29 (d, $J = 8.4$ Hz, 1H), 7.87 (d, $J = 8.4$ Hz, 1H), 7.70-7.54 (m, 3H), 7.36-7.30 (m, 6H), 7.23-7.04 (m, 6H), 5.94 (s, 1H), 4.31-4.29 (m, 2H), 3.56 (s, 1H), 1.30 (t, $J = 7.1$ Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) : δ 199.4, 169.8, 168.6, 139.5, 137.5, 134.0, 133.9, 131.7, 131.5, 129.8, 129.7, 129.0, 128.9, 128.5, 128.2(7), 128.2(5), 127.7, 126.8, 126.0, 125.6, 124.6, 122.8, 62.4, 62.0, 45.3, 14.1; IR (Film) ν : 1729, 1700, 1140 cm⁻¹; HRMS (ESI) calcd for C₃₀H₂₅O₃⁺: 433.1798. Found: 433.1800.


**(1*R*, 2*S*)-ethyl 2-(naphthalen-2-yl)-5-oxo-3,4-diphenylcyclopent-3-enecarboxylate
2h**



93% yield with 87% *ee* (Chiralcel AD-3, *i*PrOH/hexanes = 10/90, 1.0 mL/min⁻¹, λ = 290 nm; t_R (major) = 11.0 min, t_R (minor) = 13.4 min); $[\alpha]_D^{25} = + 217.7^\circ$ ($c = 0.8050$, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 7.75-7.68 (m, 4H), 7.43-7.32 (m, 7H), 7.22 (d, $J = 7.5$ Hz, 3H), 7.12-7.06 (m, 3H), 5.20 (d, $J = 2.7$ Hz, 1H), 4.36-4.21 (m, 2H), 3.71 (d, $J = 2.7$ Hz, 1H), 1.30 (t, $J = 6.9$ Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 199.4,


169.8, 168.3, 138.9, 137.8, 134.0, 133.4, 132.5, 131.2, 129.8, 129.6, 129.1, 128.9, 128.4, 128.2, 127.6, 127.1, 126.3, 126.0, 124.9, 62.4, 61.9, 51.1, 14.2; IR (Film) ν : 1703, 1626, 1332, 1141 cm^{-1} ; HRMS (ESI) calcd for $\text{C}_{30}\text{H}_{25}\text{O}_3^+$: 433.1798. Found: 433.1798.

(1*R*, 2*S*)-ethyl 3-(4-methoxyphenyl)-5-oxo-2,4-diphenylcyclopent-3-enecarboxyla-te 2i




91% yield with 78% *ee* (Chiralcel AD-3, *i*PrOH/hexanes = 10/90, 1.0 mL/min⁻¹, λ = 300 nm: t_R (major) = 11.5 min, t_R (minor) = 15.3 min); $[\alpha]_D^{25} = +195.3^\circ$ ($c = 1.0000$, CHCl_3); ¹H NMR (300 MHz, CDCl_3): δ 7.26-7.13 (m, 12H), 6.84 (d, $J = 8.7$ Hz, 2H), 4.97 (d, $J = 3.0$ Hz, 1H), 4.29-4.24 (m, 2H), 3.80 (s, 3H), 3.61 (d, $J = 2.7$ Hz, 1H), 1.31 (t, $J = 7.1$ Hz, 3H); ¹³C NMR (75 MHz, CDCl_3): δ 199.8, 168.9, 168.3, 159.5, 140.6, 138.1, 134.3, 131.0, 129.4, 129.0, 128.8, 128.2, 127.7, 127.2, 123.3, 113.8, 62.4, 61.8, 55.1, 50.9, 14.2; IR (Film) ν : 1718, 1657, 1511, 1249 cm^{-1} . HRMS (ESI) calcd for $\text{C}_{27}\text{H}_{25}\text{IO}_4^+$: 413.1747. Found: 413.1747.

(1*R*, 5*S*)-ethyl 3,4-bis(4-methoxyphenyl)-2-oxo-5-phenylcyclopent-3-enecarboxylate 2j




90% yield with 82% *ee* (Chiralcel AD-3, *i*PrOH/hexanes = 10/90, 1.0 mL/min⁻¹, λ = 327 nm; t_R (major) = 22.2 min, t_R (minor) = 25.7 min); $[\alpha]_D^{25} = +261.6^\circ$ ($c = 0.8200$, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 7.26-7.22 (m, 4H), 7.19-7.14 (m, 5H), 6.88 (d, $J = 8.8$ Hz, 2H), 6.65 (d, $J = 8.8$ Hz, 2H), 4.96 (d, $J = 2.8$ Hz, 1H), 4.28-4.24 (m, 2H), 3.82 (s, 3H), 3.72 (s, 3H), 3.56 (d, $J = 2.8$ Hz, 1H), 1.31 (t, $J = 7.0$ Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 199.5, 168.5, 168.3, 160.5, 159.3, 141.2, 137.0, 131.0, 130.9, 129.0, 127.6, 127.1, 126.3, 123.9, 113.9, 113.6, 62.5, 61.7, 55.1, 55.0, 50.5, 44.2; IR (Film) ν : 1732, 1699, 1602, 1505, 1252, 1177 cm⁻¹; HRMS (ESI) calcd for C₂₈H₂₇O₅⁺: 443.1853. Found: 443.1854.

(1*R*, 5*S*)-methyl 2-oxo-3,4,5-triphenylcyclopent-3-enecarboxylate 2k




95% yield with 90% *ee* (Chiralcel AD-3, *i*PrOH/hexanes = 10/90, 1.0 mL/min⁻¹, λ = 295 nm; t_R (major) = 9.1 min, t_R (minor) = 11.6 min); $[\alpha]_D^{25} = +278.4^\circ$ ($c = 0.99$, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 7.30-7.14 (m, 15H), 5.02 (d, $J = 1.5$ Hz, 1H), 3.80 (s, 3H), 3.66 (d, $J = 1.5$ Hz, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 199.2, 170.0, 168.7, 140.4, 138.7, 134.0, 131.2, 129.7, 129.6, 129.0, 128.9, 128.3, 128.2, 127.7, 127.3, 62.3, 52.8, 51.0; IR (Film) ν : 1725, 1695, 1341, 1139 cm⁻¹; HRMS (ESI) calcd for C₂₅H₂₁O₃⁺: 369.1485. Found: 369.1486.

**(1*R*, 2*S*)-methyl 2-(4-iodophenyl)-5-oxo-3,4-diphenylcyclopent-3-enecarboxylate
2l**




87% yield with 90% *ee* (Chiralcel AD-3, *i*PrOH/hexanes = 3/97, 1.0 mL/min⁻¹, λ = 320 nm; t_R (major) = 28.1 min, t_R (minor) = 32.6 min); $[\alpha]_D^{25} = +221.1^\circ$ ($c = 0.6450$, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 7.56 (d, $J = 8.0$ Hz, 2H), 7.31-7.16 (m, 10H), 6.91 (d, $J = 8.0$ Hz, 2H), 4.99 (d, $J = 2.0$ Hz, 1H), 3.82 (s, 3H), 3.58 (d, $J = 2.0$ Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 198.8, 169.2, 168.5, 140.1, 138.9, 138.1, 133.6, 130.9, 129.9, 129.7, 129.6, 128.9, 128.3(9), 128.3(7), 92.8, 62.0, 53.0, 50.3; IR (Film) ν : 1728, 1703, 1345, 1139 cm⁻¹; HRMS (ESI) calcd for C₂₅H₂₀IO₃⁺: 495.0452. Found: 495.0452.

4. Chemical transformations of 2a to 3a



A solution of **2a** (76.5 mg, 0.20 mmol) in anhyd THF (4.0 mL) was charged in a schlenk falk, then NaH (0.21 mmol, 5.0 mg) was added in one portion. After that, NFSI (0.2 mmol) was added and the solution was stirred at rt 4h. Pure product was obtained by flash chromatography to afford **3a** (70.4 mg, 87% yield), as a white solid.

(*1R*, *2R*)-ethyl 2-fluoro-5-oxo-2,3,4-triphenylcyclopent-3-enecarboxylate 3a³



87% yield with 90% ee (Chiralcel AD-3, *i*PrOH/hexanes = 3/97, 1.0 mL/min⁻¹, λ = 300 nm: t_R (major) = 16.0 min, t_R (minor) = 18.4 min); $[\alpha]_D^{25} = +301.8^\circ$ ($c = 0.4$, CHCl₃) ¹H NMR (300 MHz, CDCl₃): δ 7.38-7.36 (m, 3H), 7.30-7.27 (m, 2H), 7.25-7.11 (m, 10H), 4.98 (d, $J = 24.4$ Hz, 1H), 3.87 (q, $J = 3.2$ Hz, 1H), 3.66 (q, $J = 3.2$ Hz, 1H), 0.94 (t, $J = 7.2$ Hz, 3H).

5. Crystal data of 1a (ccdc 1029676)







Table 1. Crystal data and structure refinement for cd212116.


Identification code	cd212116
Empirical formula	C ₂₆ H ₂₂ O ₃
Formula weight	382.44
Temperature	293(2) K
Wavelength	0.71073 Å
Crystal system, space group	Monoclinic, Cc
Unit cell dimensions	a = 10.6608(8) Å alpha = 90 deg. b = 20.7410(15) Å beta = 102.307(2) deg. c = 9.9455(7) Å gamma = 90 deg.
Volume	2148.6(3) Å ³
Z, Calculated density	4, 1.182 Mg/m ³
Absorption coefficient	0.076 mm ⁻¹
F(000)	808
Crystal size	0.275 x 0.211 x 0.159 mm
Theta range for data collection	1.96 to 25.99 deg.
Limiting indices	-13<=h<=10, -25<=k<=25, -12<=l<=11
Reflections collected / unique	6373 / 2862 [R(int) = 0.0184]
Completeness to theta = 25.99	100.0 %
Absorption correction	Empirical
Max. and min. transmission	1.00000 and 0.58997
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	2862 / 2 / 263
Goodness-of-fit on F ²	1.048
Final R indices [I>2sigma(I)]	R1 = 0.0371, wR2 = 0.0969
R indices (all data)	R1 = 0.0404, wR2 = 0.0994
Absolute structure parameter	0.4(11)
Largest diff. peak and hole	0.122 and -0.176 e.Å ⁻³


6. Reference


1. Aggarwal, V. K.; Belfield, A. J. *Org. Lett.* **2003**, 5(26), 5075-5078.
2. Walz, I.; Togni, A. *Chem. Commun.* **2008**, 4315–4317.
3. Kawatsura, M.; Kajita, K.; Hayase, S.; Itoh, T. *Synlett* **2010**, 8, 1243–1246.


6. ^1H NMR and ^{13}C NMR Spectra of Compounds










































7. HPLC spectra of the products








PeakTable

PDA Ch1 300nm 4nm



Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.144	7082378	292134	50.412	59.058
2	12.927	6966552	202525	49.588	40.942
Total		14048929	494659	100.000	100.000



PeakTable

PDA Ch1 300nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.317	2834901	113958	92.363	94.275
2	13.572	234409	6921	7.637	5.725
Total		3069310	120878	100.000	100.000



PeakTable

PDA Ch1 297nm 4nm



Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.860	1747501	70471	50.346	62.328
2	15.988	1723491	42593	49.654	37.672
Total		3470992	113064	100.000	100.000



PeakTable

PDA Ch1 297nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.698	3484827	141519	92.759	94.800
2	15.744	272038	7763	7.241	5.200
Total		3756865	149282	100.000	100.000



PDA Ch1 254nm 4nm

PeakTable



Peak#	Ret. Time	Area	Height	Area %	Height %
1	13.007	1959279	49919	49.945	57.915
2	17.826	1963610	36274	50.055	42.085
Total		3922889	86192	100.000	100.000



PDA Ch1 300nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.839	2145644	65551	91.100	92.752
2	17.456	2096609	5123	8.900	7.248
Total		2355253	70673	100.000	100.000




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: PAP1 A, Sig=300,16 Ref=360,40

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.555	MM R	0.1394	5350.26758	609.96863	50.0839




=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs


Signal 1: DAD1 A, Sig=300,16 Ref=360,40

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.589	MM R	0.1464	1.19048e4	1314.51257	91.7450
2	8.765	MM R	0.1795	1071.16052	92.18559	8.2550

Totals : 1.29760e4 1406.69816




2g





PDA Ch1 300nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.212	1941670	87656	50.095	54.462
2	10.893	1934336	73293	49.905	45.538
Total		3876006	160949	100.000	100.000




PDA Ch1 296nm 4nm



Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.497	3997850	188487	93.021	93.785
2	11.319	299921	12490	6.979	6.215
Total		4297770	200977	100.000	100.000



PeakTable					
PDA Ch1 290nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.715	7216231	276196	50.442	55.220
2	12.863	7089788	223977	49.558	44.780
Total		14306019	500173	100.000	100.000




PeakTable					
PDA Ch1 290nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.018	6837816	228502	93.419	94.186
2	13.408	481688	14106	6.581	5.814
Total		7319504	242608	100.000	100.000



PDA Ch1 300nm 4nm

PeakTable



Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.710	1438458	51733	50.139	57.881
2	15.660	1430485	37645	49.861	42.119
Total		2868942	89378	100.000	100.000



PDA Ch1 300nm 4nm

PeakTable


Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.545	6488496	238244	88.933	91.387
2	15.349	807474	22453	11.067	8.613
Total		7295970	260697	100.000	100.000



PeakTable

PDA Ch1 327nm 4nm



Peak#	Ret. Time	Area	Height	Area %	Height %
1	22.566	1024857	18820	50.166	54.828
2	26.139	1018085	15506	49.834	45.172
Total		2042942	34326	100.000	100.000




PeakTable

PDA Ch1 320nm 4nm




Peak#	Ret. Time	Area	Height	Area %	Height %
1	22.163	9675184	178683	90.990	92.009
2	25.664	958089	15519	9.010	7.991
Total		10633273	194203	100.000	100.000





PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.286	3889046	144289	50.062	56.734
2	12.016	3879430	110036	49.938	43.266
Total		7768476	254325	100.000	100.000



PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.090	6559833	284801	94.927	95.562
2	11.641	350545	13228	5.073	4.438
Total		6910378	298028	100.000	100.000






PeakTable

PDA Ch1 300nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	17.363	4795191	118116	50.118	53.475
2	19.787	4772591	102764	49.882	46.525
Total		9567782	220881	100.000	100.000



PeakTable

PDA Ch1 300nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	16.039	5604246	133516	95.269	95.264
2	18.377	278334	6637	4.731	4.736
Total		5882580	140153	100.000	100.000